Alkermes Jumps on License Deal With Biogen -- Biotech Movers


The agreement gives Cambridge, Mass.-based Biogen an exclusive, worldwide license to commercialize ALKS 8700. Biogen will pay Alkermes a mid-teens royalty on worldwide net sales of the drug.



from Biotech News